#Canada #Kitchener #Nicoya Lifesciences #FastHDX #HDX-MS

Nicoya Lifesciences Unveils FastHDX™: A New Paradigm in Protein Dynamics

In a significant leap forward for biophysics and therapeutic discovery, Nicoya Lifesciences, Inc. has announced the launch of its groundbreaking hydrogen-deuterium exchange mass spectrometry (HDX-MS) platform, known as FastHDX™. This pioneering technology allows researchers to analyze protein structural dynamics with unprecedented detail at millisecond intervals, marking a substantial advancement over traditional methods that operate on a slower, seconds scale.

The FastHDX platform represents a 4-5 order-of-magnitude enhancement in labeling resolution, enabling scientists to observe fast, transient protein dynamics that previous techniques have overlooked. This capability opens the door to a deeper understanding of protein behavior in various disease contexts, including diabetes, cancer, and Parkinson's disease. Early adopters from both academia and the pharmaceutical sector have already validated FastHDX for probing transient allosteric states in these critical areas.

Key Features of FastHDX

One of the standout features of FastHDX is its broad labeling time range, from 50 milliseconds to over 24 hours. This flexibility allows researchers to capture rapid conformational changes while also enabling a comprehensive understanding of long-term structural modifications—all within a single platform. The system offers a millisecond labeling resolution of just 1 millisecond, which empowers researchers to discern fast protein motions and transient states that traditional HDX-MS tools are unable to detect.

Moreover, FastHDX efficiently utilizes low sample volumes of just 8 microliters, suitable for studies involving limited or high-value samples, such as peptides or those in early research phases. The platform also boasts automated capabilities, allowing for the analysis of up to six samples simultaneously in triplicate across multiple time courses. Notably, its robotic features enable unattended processing of up to 192 samples, enhancing throughput and operational efficiency.

FastHDX integrates seamlessly with standard liquid chromatography-mass spectrometry (LC-MS) workflows, meaning that adoption of this technology does not necessitate disruptive changes to existing infrastructures or retraining of research teams on completely new processes.

Scientific Impact and Future Applications

Jonathan J. Phillips from the University of Exeter remarked on the platform's capabilities, stating, "FastHDX has enabled us to capture millisecond-resolved exchange behavior and quantify low-stability structural dynamics that are otherwise inaccessible with traditional HDX-MS approaches. This development allows us to connect protein dynamics to functional outcomes in unprecedented ways." As the adoption of millisecond HDX-MS grows, it is poised to significantly change the landscape of protein motion and dynamics studies, opening new avenues for the understanding of complex diseases, biotechnology advancements, and medical therapeutics.

Ryan Denomme, CEO of Nicoya Lifesciences, highlighted the robust, automated nature of FastHDX, which was the culmination of nearly a decade of development and iterative feedback from early users. While specialized academic environments had previously employed millisecond HDX-MS, FastHDX stands as the first commercially available platform designed for real-world discovery efforts. Its maturity has garnered attention and evaluation from leading academic and pharmaceutical organizations, further solidifying its role in supporting advanced therapeutic developments.

The launch follows closely on the heels of Nicoya Lifesciences' introduction of another advanced platform, Revo, just two months earlier, showcasing the company's commitment to innovation in the field of biophysical characterization. As a market leader, Nicoya Lifesciences continues to deliver differentiated platforms that not only provide high-quality data but also ensure broad accessibility for researchers worldwide.

FastHDX is set to be unveiled at the upcoming HDX-MS conference in Strasbourg, France, from March 9-13, 2026, where it will undoubtedly attract significant interest from the scientific community eager to explore its potential applications in therapeutic development and biophysical analysis.

At its core, Nicoya Lifesciences is committed to making high-quality biophysical data more accessible and actionable, enabling researchers to glean insights on complex biologics that are critical for effective decision-making across discovery and development phases. Through its advanced analytical solutions, the company empowers scientists to ask better questions, risk less in their research, and translate data into impactful progress for human health. To learn more about Nicoya Lifesciences and its innovative offerings, visit www.nicoyalife.com or connect with them on LinkedIn.